Literature DB >> 28779025

Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis.

Rudi Alberts1, Elisabeth M G de Vries2, Elizabeth C Goode3,4, Xiaojun Jiang5,6, Fotis Sampaziotis7,8, Krista Rombouts9, Katrin Böttcher9, Trine Folseraas5,6, Tobias J Weismüller10,11, Andrew L Mason12, Weiwei Wang12, Graeme Alexander13, Domenico Alvaro14, Annika Bergquist15, Niklas K Björkström16, Ulrich Beuers2, Einar Björnsson17, Kirsten Muri Boberg5,18, Christopher L Bowlus19, Maria C Bragazzi20, Marco Carbone21, Olivier Chazouillères22, Angela Cheung23, Georgios Dalekos24, John Eaton25, Bertus Eksteen26, David Ellinghaus27, Martti Färkkilä28, Eleonora A M Festen1, Annarosa Floreani29, Irene Franceschet30, Daniel Nils Gotthardt31, Gideon M Hirschfield32, B van Hoek33, Kristian Holm5,6, Simon Hohenester34, Johannes Roksund Hov5,6, Floris Imhann1, Pietro Invernizzi21, Brian D Juran25, Henrike Lenzen10, Wolfgang Lieb35,36, Jimmy Z Liu37, Hanns-Ulrich Marschall38, Marco Marzioni39, Espen Melum5,6, Piotr Milkiewicz40, Tobias Müller41, Albert Pares42, Christian Rupp43, Christian Rust44, Richard N Sandford4, Christoph Schramm45, Stefan Schreiber27,46, Erik Schrumpf6,47, Mark S Silverberg48, Brijesh Srivastava4, Martina Sterneck49, Andreas Teufel50, Ludovic Vallier7,37, Joanne Verheij51, Arnau Vich Vila1, Boudewijn de Vries1, Kalliopi Zachou52, Roger W Chapman53, Michael P Manns10,11, Massimo Pinzani9, Simon M Rushbrook3, Konstantinos N Lazaridis25, Andre Franke27, Carl A Anderson37, Tom H Karlsen5,6, Cyriel Y Ponsioen2, Rinse K Weersma1.   

Abstract

OBJECTIVE: Primary sclerosing cholangitis (PSC) is a genetically complex, inflammatory bile duct disease of largely unknown aetiology often leading to liver transplantation or death. Little is known about the genetic contribution to the severity and progression of PSC. The aim of this study is to identify genetic variants associated with PSC disease progression and development of complications.
DESIGN: We collected standardised PSC subphenotypes in a large cohort of 3402 patients with PSC. After quality control, we combined 130 422 single nucleotide polymorphisms of all patients-obtained using the Illumina immunochip-with their disease subphenotypes. Using logistic regression and Cox proportional hazards models, we identified genetic variants associated with binary and time-to-event PSC subphenotypes.
RESULTS: We identified genetic variant rs853974 to be associated with liver transplant-free survival (p=6.07×10-9). Kaplan-Meier survival analysis showed a 50.9% (95% CI 41.5% to 59.5%) transplant-free survival for homozygous AA allele carriers of rs853974 compared with 72.8% (95% CI 69.6% to 75.7%) for GG carriers at 10 years after PSC diagnosis. For the candidate gene in the region, RSPO3, we demonstrated expression in key liver-resident effector cells, such as human and murine cholangiocytes and human hepatic stellate cells.
CONCLUSION: We present a large international PSC cohort, and report genetic loci associated with PSC disease progression. For liver transplant-free survival, we identified a genome-wide significant signal and demonstrated expression of the candidate gene RSPO3 in key liver-resident effector cells. This warrants further assessments of the role of this potential key PSC modifier gene. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Primary sclerosing cholangitis; genetics; liver transplantation

Mesh:

Substances:

Year:  2017        PMID: 28779025      PMCID: PMC5797498          DOI: 10.1136/gutjnl-2016-313598

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  37 in total

Review 1.  Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review.

Authors:  Kirsten Boonstra; Ulrich Beuers; Cyriel Y Ponsioen
Journal:  J Hepatol       Date:  2012-01-13       Impact factor: 25.083

2.  Genomic spectra of biliary tract cancer.

Authors:  Hiromi Nakamura; Yasuhito Arai; Yasushi Totoki; Tomoki Shirota; Asmaa Elzawahry; Mamoru Kato; Natsuko Hama; Fumie Hosoda; Tomoko Urushidate; Shoko Ohashi; Nobuyoshi Hiraoka; Hidenori Ojima; Kazuaki Shimada; Takuji Okusaka; Tomoo Kosuge; Shinichi Miyagawa; Tatsuhiro Shibata
Journal:  Nat Genet       Date:  2015-08-10       Impact factor: 38.330

Review 3.  Towards an integrated view of Wnt signaling in development.

Authors:  Renée van Amerongen; Roel Nusse
Journal:  Development       Date:  2009-10       Impact factor: 6.868

4.  Genome-wide association study identifies variants associated with autoimmune hepatitis type 1.

Authors:  Ynto S de Boer; Nicole M F van Gerven; Antonie Zwiers; Bart J Verwer; Bart van Hoek; Karel J van Erpecum; Ulrich Beuers; Henk R van Buuren; Joost P H Drenth; Jannie W den Ouden; Robert C Verdonk; Ger H Koek; Johannes T Brouwer; Maureen M J Guichelaar; Jan M Vrolijk; Georg Kraal; Chris J J Mulder; Carin M J van Nieuwkerk; Janett Fischer; Thomas Berg; Felix Stickel; Christoph Sarrazin; Christoph Schramm; Ansgar W Lohse; Christina Weiler-Normann; Markus M Lerch; Matthias Nauck; Henry Völzke; Georg Homuth; Elisabeth Bloemena; Hein W Verspaget; Vinod Kumar; Alexandra Zhernakova; Cisca Wijmenga; Lude Franke; Gerd Bouma
Journal:  Gastroenterology       Date:  2014-04-23       Impact factor: 22.682

5.  Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis.

Authors:  Kirsten Boonstra; Rinse K Weersma; Karel J van Erpecum; Erik A Rauws; B W Marcel Spanier; Alexander C Poen; Karin M van Nieuwkerk; Joost P Drenth; Ben J Witteman; Hans A Tuynman; Anton H Naber; Paul J Kingma; Henk R van Buuren; Bart van Hoek; Frank P Vleggaar; Nan van Geloven; Ulrich Beuers; Cyriel Y Ponsioen
Journal:  Hepatology       Date:  2013-10-17       Impact factor: 17.425

6.  Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis.

Authors:  Jason H Cheng; Hongyun She; Yuan-Ping Han; Jiaohong Wang; Shigang Xiong; Kinji Asahina; Hidekazu Tsukamoto
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2007-11-15       Impact factor: 4.052

7.  Association of primary sclerosing cholangitis with HLA-B8.

Authors:  R W Chapman; Z Varghese; R Gaul; G Patel; N Kokinon; S Sherlock
Journal:  Gut       Date:  1983-01       Impact factor: 23.059

Review 8.  Primary sclerosing cholangitis.

Authors:  Gideon M Hirschfield; Tom H Karlsen; Keith D Lindor; David H Adams
Journal:  Lancet       Date:  2013-06-28       Impact factor: 79.321

9.  Genetic modifiers of liver disease in cystic fibrosis.

Authors:  Jaclyn R Bartlett; Kenneth J Friedman; Simon C Ling; Rhonda G Pace; Scott C Bell; Billy Bourke; Giuseppe Castaldo; Carlo Castellani; Marco Cipolli; Carla Colombo; John L Colombo; Dominique Debray; Adriana Fernandez; Florence Lacaille; Milan Macek; Marion Rowland; Francesco Salvatore; Christopher J Taylor; Claire Wainwright; Michael Wilschanski; Dana Zemková; William B Hannah; M James Phillips; Mary Corey; Julian Zielenski; Ruslan Dorfman; Yunfei Wang; Fei Zou; Lawrence M Silverman; Mitchell L Drumm; Fred A Wright; Ethan M Lange; Peter R Durie; Michael R Knowles
Journal:  JAMA       Date:  2009-09-09       Impact factor: 56.272

10.  Imputing amino acid polymorphisms in human leukocyte antigens.

Authors:  Xiaoming Jia; Buhm Han; Suna Onengut-Gumuscu; Wei-Min Chen; Patrick J Concannon; Stephen S Rich; Soumya Raychaudhuri; Paul I W de Bakker
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

View more
  12 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

2.  Proteasomal Degradation of Enhancer of Zeste Homologue 2 in Cholangiocytes Promotes Biliary Fibrosis.

Authors:  Nidhi Jalan-Sakrikar; Thiago M De Assuncao; Guang Shi; Sayed Obaidullah Aseem; Cheng Chi; Vijay H Shah; Robert C Huebert
Journal:  Hepatology       Date:  2019-06-22       Impact factor: 17.425

Review 3.  The intestinal and biliary microbiome in autoimmune liver disease-current evidence and concepts.

Authors:  Timur Liwinski; Melina Heinemann; Christoph Schramm
Journal:  Semin Immunopathol       Date:  2022-05-10       Impact factor: 11.759

4.  Primary Sclerosing Cholangitis, Part 1: Epidemiology, Etiopathogenesis, Clinical Features, and Treatment.

Authors:  James H Tabibian; Ahmad H Ali; Keith D Lindor
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-05

5.  A distinct gut microbiota composition in patients with ankylosing spondylitis is associated with increased levels of fecal calprotectin.

Authors:  Eva Klingberg; Maria K Magnusson; Hans Strid; Anna Deminger; Arne Ståhl; Johanna Sundin; Magnus Simrén; Hans Carlsten; Lena Öhman; Helena Forsblad-d'Elia
Journal:  Arthritis Res Ther       Date:  2019-11-27       Impact factor: 5.156

6.  Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis.

Authors:  Christian Rupp; Theresa Hippchen; Thomas Bruckner; Petra Klöters-Plachky; Anja Schaible; Ronald Koschny; Adolf Stiehl; Daniel Nils Gotthardt; Peter Sauer
Journal:  Gut       Date:  2019-03-25       Impact factor: 23.059

7.  Epigenetic Signatures Discriminate Patients With Primary Sclerosing Cholangitis and Ulcerative Colitis From Patients With Ulcerative Colitis.

Authors:  Manon de Krijger; Ishtu L Hageman; Andrew Y F Li Yim; Jan Verhoeff; Juan J Garcia Vallejo; Patricia H P van Hamersveld; Evgeni Levin; Theodorus B M Hakvoort; Manon E Wildenberg; Peter Henneman; Cyriel Y Ponsioen; Wouter J de Jonge
Journal:  Front Immunol       Date:  2022-03-16       Impact factor: 7.561

8.  [Surgical treatment of primary sclerosing cholangitis : Experiences from 30 years in a single center cohort with 173 consecutive patients].

Authors:  Vittorio Branchi; Tobias J Weismüller; Taotao Zhou; Jonas Henn; Alexander Semaan; Tim R Glowka; Maria Gonzalez-Carmona; Christian Strassburg; Jörg C Kalff; Steffen Manekeller; Hanno Matthaei
Journal:  Chirurg       Date:  2021-02       Impact factor: 0.955

9.  PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC.

Authors:  Beata Kruk; Roman Liebe; Małgorzata Milkiewicz; Ewa Wunsch; Joanna Raszeja-Wyszomirska; Frank Lammert; Piotr Milkiewicz; Marcin Krawczyk
Journal:  PLoS One       Date:  2018-08-30       Impact factor: 3.240

10.  Genetic variants at the 16p13 locus confer risk for eosinophilic esophagitis.

Authors:  Leah C Kottyan; Avery Maddox; Julian R Braxton; Emily M Stucke; Vince Mukkada; Philip E Putnam; J Pablo Abonia; Mirna Chehade; Robert A Wood; Robbie D Pesek; Brian P Vickery; Glenn T Furuta; Peter Dawson; Hugh A Sampson; Lisa J Martin; Jennifer A Kelly; Robert P Kimberly; Kathy Sivils; Patrick M Gaffney; Kenneth Kaufman; John B Harley; Marc E Rothenberg
Journal:  Genes Immun       Date:  2018-06-08       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.